NRG Therapeutics

Raised $67.6M in a Series B round, announced 8 September 2025.

Total raised: $67.6M

Latest round Series BCountry United KingdomSector Health

Round

$67.6MSeries B, 8 September 2025

Series B to move lead candidate NRG5051 into the clinic in early 2026.

Amount: $67.6M
Stage: Series B
Announced: 8 September 2025
Lead: SV Health Investors (Dementia Discovery Fund)
Other investors: British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, Brandon Capital
Use of funds: Series B to move lead candidate NRG5051 into the clinic in early 2026.
Checked: Amount and date matched across 2 press sources
Sources: NRG Therapeutics raises €58M (Series B) - Tech.eu Funding Explorer tech.eu
NRG Therapeutics raises €58M (Series B) - Tech.eu Funding Explorer funding.tech.eu

Company

Small-molecule drugs targeting mitochondrial pore for ALS and Parkinson's

Based in: Stevenage, United Kingdom
Sector: Health
Website: nrgtherapeutics.com ↗

Questions

How much has NRG Therapeutics raised?

NRG Therapeutics raised $67.6M in a Series B round, announced on 8 September 2025.

Who invested in NRG Therapeutics?

SV Health Investors (Dementia Discovery Fund) led. Investors include SV Health Investors (Dementia Discovery Fund), British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures and Omega Funds.